None listed
Conditions
Brief summary
An Open-label, Single-Dose, 3-Period Crossover Study To Evaluate the 2-Way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects MK0431G (combination treatment) is being developed for treatment of patients for whom treatment with both Sitagliptin and Losartan is appropriate. However, this study is in healthy volunteers only.
Interventions
Treatment A: Sitagliptin 100mg (oral tablet)
Treatment B: Losartan 100mg (oral tablet)
Treatment C: Sitagliptin 100mg (oral tablet) + Losartan 100mg (oral tablet)
Each participant receives each of the treatments (A, B, C) once as a single oral dose with a seven day wash-out period in between doses. The order in which they receive the treatments is randomized.
MK0431G (combination treatment) is being developed for treatment of patients for whom treatment with both Sitagliptin and Losartan is ap
Treatment A: Sitagliptin 100mg (oral tablet) Treatment B: Losartan 100mg (oral tablet) Treatment C: Sitagliptin 100mg (oral tablet) + Losartan 100mg (oral tablet) Each participant receives each of the treatments (A, B, C) once as a single oral dose with a seven day wash-out period in between doses. The order in which they receive the treatments is randomized. MK0431G (combination treatment) is being developed for treatment of patients for whom treatment with both Sitagliptin and Losartan is appropriate. However, this study is in healthy volunteers only.
Sponsors
Merck Sharp and Dohme Corp, a subsidiary of Merck & Co., Inc.
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
-Subject judged to be in good health based on medical history, physical examination, ECG, vital sign measurements and laboratory safety tests -Non-smoker -BMI <30kg/m2
Exclusion criteria
-Mentally or legally incapacitated or having significant emotional problems or has a history of clinically significant psychiatric disorder -History of any clinically significant diseases/disorders, myopathic disorder or history of rhabdomyolysis. -Creatinine clearance <80mL/min -History of neoplastic disease -Pregnant, breast feeding or expecting to conceive -Major surgery or blood donation within 4 weeks -Consumes excessive amounts of alcohol or caffeine -History of significant allergies, anaphylactic reaction or significant intolerance to prescription/non-prescription drugs or food. -Regular/recreational drug user -History of hypersensitivity to sitagliptin, losartan or any of the tablet excipients
Outcome results
None listed